Will Lihai Biological Company develop African swine fever?

According to relevant information, Lihai Biological Company is developing African swine fever. With the approval of the Ministry of Agriculture and Rural Affairs, Lihai Bio conducted clinical trials of African swine fever vaccine in Heilongjiang, Henan and Xinjiang in early April, early May and early June of 2002/KLOC-0, with a trial scale of nearly 3,000 commercial fattening pigs. The immunized pigs grew well and had no obvious clinical adverse reactions. There were no obvious pathological changes, no vaccine virus discharge and no horizontal transmission in the autopsy of immunized pigs. Immunized pigs were attacked by strong virus in high-grade biosafety laboratory, and the immune protection rate of different dose inoculation groups was above 80%.